Friday, 25 November 2016

Near term growth concerns to weigh on Sun Pharma

For daily intraday tips and intraday calls click this link to get connect with us fill our Two Days Free Trial For more you can give One missed call on this no. -9303093093 


Sun Pharma has acquired 85% stake in OJSC Biosintez, a Russian company. With that, it gets a facility in Russia, which saw total pharma distributor-to-retailer sales of $10 billion in 12 months to September 2016. Russia and Commonwealth of Independent States (countries part of the Soviet Union) saw $200 million in sales in FY16. 


The facility in Russia can drive growth as local units there are needed to bid for government projects. The government accounts for about 30% of total market. Thus, acquisition at enterprise value to sales ratio of 1.15 is attractive.

No comments:

Post a Comment